Entities

Vensana Capital Management, LLC is a U.S. medical-technology venture capital and growth equity manager founded in 2019 by Justin Klein and Kirk Nielsen, with offices in Minneapolis and the Washington, D.C. area. It backs development- and commercial-stage medical devices, diagnostics, life-science tools and data-science businesses. The independent manager launched with enabling support from Versant Ventures; historic investments made at NEA or Versant are not automatically assigned as new Vensana checks. Its AI portfolio includes Cleerly’s coronary CT analysis, Apella’s ambient AI and computer vision for hospitals, and Volta Medical’s AI-assisted cardiac electrophysiology. Its neuroscience-related investing and professional expertise include Relievant’s pain-intervention technology and advisors with neuromodulation, epilepsy and brain-tumor treatment experience; advisors’ prior operating companies are not inferred Vensana investments. The current public directory names fifteen core professionals and twenty-eight advisor cards, with Bill Hoffman appearing in both; advisor outside-company titles may describe historical experience. Three actual funds closed at USD225 million in 2019, USD325 million in 2021 and USD425 million announced in January 2025. Approximately USD1 billion in capital under management is an aggregate, not an additional fund. Vensana Innovation, launched in October 2025 and led by Venture Partner Thomas Tu, is its company-building platform, not an invented standalone fundraising vehicle. Existing Cleerly financing participations and personal attributions remain preserved under canonical Investor4629.

AI investment and company-building platform combining early-stage venture investing, incubation and transformation buyouts. Its venture fund invests from pre-seed through Series A in B2B software and healthcare, while its studios and Propel strategy apply AI to established industries.

Flare Capital Partners is a healthcare technology venture investor managed by Flare Capital Management Company, LLC (SEC adviser CRD161805). The brand succeeded Foundation Medical Partners in April 2015. It backs companies applying software, data science and artificial intelligence to healthcare delivery, clinical technology and payer/provider infrastructure, including mental-health and neuroscience-related platforms. Its public network comprises an investment and operating team, executive partners, an external industry advisory board, an external AI advisory council and the 2026 Flare Scholars cohort; network participants are distinguished from firm employees. Primary closing announcements verify USD200 million for Fund I in2015, USD255 million for Fund II in2019 and USD350 million for Fund III in2022. The current adviser filing additionally reports a Fund I-A parallel vehicle and Select Strategies I; neither is assigned an unverified closed amount, and adviser assets are not substituted for cash fund commitments.

Frazier Life Sciences invests globally in companies developing new medicines, combining venture capital, company creation and public-equity investing. Its venture team forms and finances product-focused biopharmaceutical companies, emphasizes preclinical-to-clinical development and Series A investing, and supports companies through later private rounds and commercialization. Its long-only public strategy invests in small- and mid-cap biotechnology companies and selected private crossover financings. Investors, scientific advisers and operating professionals help assess biology, clinical programs and commercial opportunities, recruit management and build new companies. Its portfolio includes therapies for immune disorders and neurological disease; Sudo Biosciences develops brain-penetrant TYK2 inhibitors for multiple sclerosis and neuroinflammation. Frazier Life Sciences is operated by Frazier Life Sciences Management, L.P.; this profile is distinct from the Frazier Healthcare Partners healthcare-buyout business.

Intrepid Growth Partners invests growth capital in companies applying artificial intelligence to established commercial markets. Founded by Mark Machin, Mark Shulgan and Ajay Agrawal, it backs AI businesses in industrial engineering, healthcare, cybersecurity, advertising and enterprise software, with investment teams in Toronto and London. Its first fund closed at US$525 million in September 2026. Growth partners and scientific advisers support portfolio companies with AI research, product development and international expansion.

Kearny Jackson is an early-stage venture capital firm co-founded by Sunil Chhaya and Sriram Krishnan, with a public focus on pre-seed and seed B2B software, AI, developer infrastructure, fintech infrastructure and enterprise tooling. Its name refers to the San Francisco street intersection where the founders met; the founders combine institutional venture investment and technology operating backgrounds. Its current public team lists both founders as General Partners. The Kearny Jackson Sriram Krishnan is the Malaysia-born National University of Singapore alumnus linked to linkedin.com/in/sriramkrishnan/, a different person from the former Andreessen Horowitz partner and White House adviser linked to sriramkrishnan01; their personal profiles and investment graphs are preserved separately. The firm’s own current strategy describes typical investments up to USD2M, a guideline rather than an actual issuer allocation. Its own portfolio includes AI coding company Cognition, AI-native legal platform Sandstone, Bedrock Robotics, MotherDuck, Genesis AI, Cara, Comulate and other software/infrastructure businesses. A portfolio card alone does not prove round, date, ticket, institutional-versus-personal attribution or a follow-on check. The official August6,2025 SEC amendment names Kearny Jackson Fund III, L.P., parallel Fund III-A, L.P., and their general partner Kearny Jackson Fund III GP, LLC, with Sunil Chhaya and Sriram Krishnan as managing directors. The combined offering reported USD66,761,625 sold and zero remaining, superseding the manager’s July2024 USD65M fund-launch announcement without recording duplicate cash or assigning the aggregate to each parallel vehicle. Fund II is independently confirmed operational by the manager’s January2023 announcement; its exact primary-source closed amount remains unverified. The public brand’s precise operating-adviser legal name/registration is not asserted from generic corporate aggregators. Existing financial IDs and unrelated homonyms remain preserved.

Korea Investment Partners Co., Ltd. (한국투자파트너스㈜, KIP) is the Korean venture-capital and private-equity manager incorporated in1986 and affiliated with Korea Investment Holdings. Its official group-domain site partners.koreainvestment.com, own kipvc.com/kipvc.co.kr sites and parent’s global network identify the manager. It is distinct from the parent financial holding company, Korea Investment & Securities, Korea Investment Corporation sovereign investor, Korea Investment Private Equity, and unrelated similarly named funds. The retained Adex GoldiKoreaInvestmentPartners/Investor4486 identifies the venture manager, preserving its existing InvestmentFirm type, private checks and Goldilocks references. KIP invests across early-stage ventures and growth businesses, with portfolio support, business development and international expansion. Its published sectors cover biotech and healthcare (including medical imaging, cell therapy and therapeutics), ICT/AI, autonomous mobility, semiconductors and industrial sensors, consumer/fintech, and media. Its own portfolio includes clinical/genomic and medical-robotic technologies alongside AI software and industrial deeptech. Current portfolio inclusion, IPO/M&A labels and a professional’s career investment history are not proof of current holdings, personal checks or additional priced rounds. The live official directory’s public team endpoint names82 people in management, venture investment, PE, legal, compliance, risk, operations, China, US and Singapore categories. Each has a named original publisher portrait. Current CEO Mahnsoon Hwang has pharmacy and biotech research/industry experience; CIO Dongyeob Kim leads investment strategy. The published global-office professionals are scoped regional-platform affiliations, not an assertion that every professional is employed by the same Korean contracting entity. Current source-backed titles and fuller workclass fields are used where individual card titles are empty. Older indexed roster spelling/job captions are not promoted over the live endpoint, which includes David Suh’s2026 US appointment. The own history expressly reports KIP FundI closed in1987, KIP China FundI in2011, and KIP PE FundI in2015; these are source-published names and years, with legal suffixes, corpus and exact closing dates undisclosed. Its2019 Singapore co-GP fund close is described but no invented legal fund name is created. Regional vehicles/GPs may differ from the Korean parent manager. AUM, assets, investment totals, managed-corpus claims and website counters are not new LP proceeds or company financing amounts. Riyadh Valley Company’s own25March2021 release explicitly names Korea Investment Partners in a completed Global Kinetics Pty Ltd financing alongside BioScience and Brandon/MRCF. Exact cash, stage, ticket and closing day are unpublished; a later PKG brand reference is not a separate2023 follow-on check. The issuer-owned participation is added only after this full manager core is verified. All six inherited investments remain unchanged.

Morningside Ventures is the Boston-area private investment group founded by the Chan family in 1986. Its current own mandate spans life sciences, digital health, artificial intelligence, materials and technology, with patient, long-term company-building capital. Its neuroscience portfolio includes Neuroelectrics, Prilenia and Nocion; other digital-health and AI investments include Curai Health and Generate Biomedicines. The public brand at morningside.com is supported by issuer references naming Morningside Ventures and named professionals affiliated with Morningside Technology Advisory LLC. Advisory affiliations, concurrent portfolio-company operating roles and former employees are explicitly qualified. SEC documents identify investment-holding entities including Morningside Venture Investments Limited, Morningside Technology Ventures Limited and Golwyn Capital Appreciation Limited; these are holding vehicles, not verified third-party LP fund closes. No independently verified closed-fund capital amount or current AUM is asserted. The separate generic Morningside database record remains protected because its mixed historical portfolio includes unresolved China and US identity references; no automatic merger with former China Morningside/5Y Capital, Morningside AI, Bulgarian Morningside Hill or unrelated US investment managers is made. Published primary team and issuer sources are enriched as available; the own site does not publish a comprehensive named staff directory.

US early-stage venture firm founded in 2019 as Concrete Rose and renamed Westbound Equity Partners in 2024. It invests at pre-seed and seed across technology sectors, including AI, healthcare, enterprise software and climate technology, backing founders who build diverse teams and create opportunities for underrepresented communities. It provides capital, operating advice and access to a network of entrepreneurs and investors. Its oversubscribed $100 million Fund II was announced in March 2024.

SPEEDRUN is Andreessen Horowitz’s early-stage startup investment and accelerator program, launched in 2023. It is a program within a16z rather than an independently established investment firm; this existing organizational record retains its historical classification to preserve relationships. SPEEDRUN supports founders building AI, software, games, entertainment and other technology companies through a 12-week in-person program in San Francisco, funding and operational support across recruiting, go-to-market, finance, legal, people practices, marketing, visas and fundraising. The current program advertises up to USD1 million of investment per accepted company plus more than USD10 million of vendor credits, with investment terms specified in its FAQ; credits and conditional follow-on funding are distinct from an immediately closed cash round. Its own current website reports more than USD300 million deployed across over 300 startups since launch, representing historical deployment rather than a separately verified fund close. Current primary investment biographies include Andrew Chen and Jonathan Lai as general partners, Joshua Lu and other investment partners, and Fareed Mosavat and Marcus Segal as venture partners. The a16z directory explicitly associates 41 published people with SPEEDRUN, including shared operational functions and SPEEDRUN Alpha. Verified institutional investment records include Fundamental Research Labs, nunu.ai, Dex and TaleMonster Games. Fund legal names and closed fund sizes are not inferred from parent a16z assets under management or program deployment.

APA Venture Partners is an early-stage venture capital firm investing in businesses that automate established industries. It combines financing with operational support and enterprise networks to help founders establish product-market fit and grow. Its published portfolio includes GreyscaleAI’s AI and X-ray inspection systems, dataPlor’s location intelligence, FoodReady’s food-safety automation, Terminal49’s logistics software and Sevaro’s virtual neurology services. The associated legal manager is APA VP Management Company, LLC, named in SEC filings for APA Venture Partners Fund I, LP; APA Venture Partners Fund I GP, LLC is that vehicle’s general partner. Fund I reported USD3.125 million in subscriptions sold to43 investors in December2022; this is a reported fundraising snapshot, not an independently verified final close. The current website does not publish a named team directory. SEC filings identify Ajay Sharma and Paul Kirincich as managers in2022, with Charles Kaufman also named in2021; a September2025 event lists Alex Kaufman as an APA partner. Those affiliations are dated and the Charles/Alex identity relationship remains unverified. The firm is distinct from North Carolina hospitality operator APA Ventures, Apax Partners and APA Engineering.

Accelmed Partners is a U.S.-based private-equity firm investing in commercial-stage healthcare technology businesses across medical devices, diagnostics, digital health and technology-enabled healthcare services. Founded by Uri Geiger with backing from Mori Arkin, its control and growth strategies combine operational support with technology and product development. Its portfolio includes brain-responsive epilepsy devices at NeuroPace, prescription digital therapeutics at Click Therapeutics and artificial-intelligence patient monitoring at AiCure. The current public team lists nine investment, clinical, regulatory, technology and advisory professionals. Accelmed Partners I closed in 2016 with USD130 million of commitments; Partners II announced its completed USD400 million hard-cap close in March2021. The separate historic Accelmed Ventures strategy and pre-fund investments are explicitly labelled by its own website and are not automatically Partners I or II investments. Partners II Management LLC, the fund and its general-partner entities are legally distinct; this retained profile represents the verified public manager brand rather than assuming all entities are a single cash subscriber. Corporate valuations, acquisition consideration, portfolio revenue, fund targets, co-investments and assets managed are not additional fund closes.

BMW i Ventures invests in companies developing technology for automotive, manufacturing, supply chains, energy and sustainability. Its latest fund backs physical AI, AI agents, industrial software, advanced materials and circular-economy technologies, with access to BMW’s technical and commercial network.

Baidu Ventures (BV) is an independent venture-capital firm initiated by Baidu Group in 2017. It backs early-stage artificial-intelligence businesses across generative AI, embodied intelligence and robotics, autonomous driving, advanced computing and life sciences. Its current official directory names Xue Gao as CEO and managing partner and Jinling Zhang as CFO and managing partner. The firm operates from Beijing and manages both dollar and renminbi funds; its website reports more than 200 portfolio companies worldwide. Baidu Ventures is distinct from Baidu’s corporate investment department and Baidu Capital. The English singular-domain site is currently offline at its CDN; the live plural-domain official site provides the current named team, original portraits and brand asset. An issuer-attributed 2021 statement reports completion of its third fund at USD400 million, with no exact closing day or legal vehicle name established. The Cayman vehicle BV Fund II L.P. has a separately identified general partner, Baidu Ventures GP II, L.P.; its legal existence does not establish its final cash size. Parent ownership, assets under management, targets and portfolio partnership dates are not recorded as company financing or fund closes.

Provides GPU cloud infrastructure for training and running AI models, with managed computing capacity and related developer services.

Corewell Health Ventures is the corporate healthcare investment and strategic-partnership platform of Corewell Health Ventures, LLC, a Michigan company wholly owned by the nonprofit Corewell Health system. Current regulator and historical IRS records establish continuity with Spectrum Health Ventures, LLC through EIN 81-5424150; the exact legal rename day is unpublished. Its 2017 launch contemplated investing up to USD100 million over a decade, an investment ceiling rather than a closed external LP fund or proven paid capital. The platform backs healthcare services, digital health, medical devices and technologies aligned with health-system needs, and publishes five current team members. Its own portfolio distinguishes direct company investments, indirect exposure through investment partners and strategic partnerships. Direct holdings include chronic-pain care company Override, AI radiology company Rad AI, remote-monitoring company Cadence and clinical data and device businesses. Indirect holdings are not attributed as direct company cash checks. Corewell Health Innovation, LLC is a distinct controlled subsidiary, not an additional investor in the same transaction. The inherited InvestmentFirm database type is retained; this describes a corporate LLC investing unit, not an independent nonprofit foundation or assumed external venture fund.

Gates Ventures LLC is Bill Gates’ private executive office, established in September 2008 and led by CEO Larry Cohen. Its own public profile identifies Seattle, Washington as its headquarters; a published research agreement identifies a Kirkland office. The office supports Gates’ work by incubating products, undertaking research and advocacy, building partnerships and managing venture investments. Its health and life-sciences work is directly relevant to neuroscience and artificial intelligence: Alzheimer’s research data infrastructure, diagnostic biomarkers, speech-based research, imaging platforms and computational drug-discovery collaborations. Public partners identify participation in the Alzheimer’s Disease Data Initiative, the Global Research and Imaging Platform and the Diagnostics Accelerator with the Alzheimer’s Drug Discovery Foundation. NeuroVision Imaging’s current investor directory independently identifies Gates Ventures as an institutional investor; it does not disclose an investment date, stage or allocation. The office also supports academic digital-health research grants, which are not equated with company equity investments or capital raised by the office. Gates Ventures is a private office rather than a publicly verified outside-LP venture fund manager. The existing database InvestmentFirm category is retained, with this institutional qualification. It is distinct from the Gates Foundation, Gates Frontier and Bill Gates’ personal investor identity. Publicly available team affiliations include current employees, advisers and explicitly qualified former or source-dated roles; the reviewed sources do not expose a complete private employee directory. No verified outside-LP fund close or office-level cash fundraising event was found in the reviewed primary sources.

Innovation Industries invests in and helps build European deep-tech companies commercialising complex technologies in industrial technology, medical technology and food and agricultural technology. It provides long-term capital and hands-on technical, operational and governance support, from early-stage company formation through growth. Its investment focus includes semiconductors, quantum computing, advanced manufacturing, diagnostics and medical devices, particularly in the Benelux and Germany. A separate Strategic Partners Fund finances scale-ups already in its portfolio.

McKesson Ventures is the corporate investment arm of McKesson, backing venture and growth-stage companies that develop software and services for healthcare and the pharmaceutical industry. Its focus includes healthcare data and analytics, biopharma services, clinical research, medication management and AI-enabled workflows. It expanded into growth equity in 2025.

SBI Investment Co., Ltd. is the Japanese venture-capital fund operator and investment manager within the SBI Group, establishedJune7,1996 and registered for TypeII financial-instruments and investment-management business with the KantoLocalFinanceBureau(FIBO3397). Its current public strategy covers AI, robotics, biotechnology/healthcare, digital infrastructure and fintech, with hands-on business-development support. It operates Nikon-SBI Innovation Fund, jointly established with Nikon onJuly1,2016, and Nikon-SBI Innovation FundII establishedNovember2023. These are managed corporateventure funds, distinct from Nikon’s own corporate identity and SBIHoldings as parent. The primary current CVC table explicitly reports committed capital of10BJPY forFundI and5BJPY forFundII; the2016 launch had described10BJPY as planned. Committed fund capital is not a company investment cash disbursement or managerAUM. The June30,2026 corporate roster names six directors and one auditor. Additional named venturecapitalist affiliation is source-qualified to the ownNovember2025 announcement. Broad portfolio statistics1,314companies/219exits are published asofMarch31,2025, not asserted as real-time2026counts. Existing firm investor identity and historical checks are retained; fund-specific issuer checks identify the underlying named vehicle in evidence.

Valtruis is a healthcare investment and company-building platform launched by Welsh, Carson, Anderson & Stowe (WCAS) in August 2021. It invests in and partners with businesses changing how healthcare is accessed, delivered, experienced and paid for, with a focus on value-based care. Its investor and operator team provides strategic relationships and operational support across finance, people, data and analytics, actuarial science and risk contracting. The current published directory includes 17 team members and six executive advisors. Its investments include healthcare agentic AI company Autonomize AI, AI-based virtual neuroscience company Sevaro, real-world clinical evidence platform Atropos Health, and value-based care infrastructure company Arbital Health. WCAS announced an initial USD300 million commitment to the corporate platform at launch; this is not a verified external LP fund cash close or an independently raised USD300 million fund. Valtruis is the institutional investment platform, distinct from its parent WCAS and from private personal investments by individual team members. Legacy InStride company aliases and several funding dates require a separate full issuer audit; existing references are preserved pending that review.

Virtue is a venture capital firm backing healthcare startups at pre-seed and seed stages. It invests in clinical AI, healthcare data infrastructure, biopharma software and new care-delivery models, including neurology practices, autism care and serious mental illness care. Its typical initial investment is USD 500,000 to USD 4 million.

20SALES is an early-stage B2B software investment collective whose eight published general partners bring sales, customer-success and go-to-market operating experience from companies including Slack, Salesforce, Dropbox, OpenAI, Webflow, Vanta and Twilio. The US-facing 20sales.vc platform targets seed and Series A businesses and supports founders with enterprise sales, product-led growth, retention, recruiting and revenue operations. Its inaugural Delaware legal vehicle is Fund I, a series of 20Sales, LP, formed in 2023; the SEC filing reports USD5 million fully sold to 14 investors with zero remaining. Fund GP, LLC is its general partner and Belltower Fund Group Ltd. manages that GP. These administrative entities are distinguished from the public operating partners. The fund’s exact final closing day is not disclosed. Published collective revenue experience and indicative future check sizes are not fund capital or individual investment tickets. A separate 20SALES II European operator strategy at 20sales.ai is powered by 20VC; its statutory continuity with this first vehicle and its closed size have not been independently established, so its separate roster and portfolio are not automatically assigned here.

AirAngels is an early-stage investment platform formed by Airbnb alumni, combining an operator community, a deal-by-deal AngelList syndicate and pooled venture vehicles. Its current airangels.co address redirects to its public AngelList profile, whose legal disclosure identifies affiliation with AirAngels Management, LLC. The adviser’s official IAPD record identifies CRD313675 / SEC802-135655 and active exempt-reporting status as of February23,2026. The public syndicate names Daniel Rumennik and Lenny Rachitsky; its own Fund I launch and a2026 firsthand interview also identify Michelle Kwon’s founding and continuing fund role. The broad technology portfolio includes climate/data businesses and neurological-care investor activity through Isaac Health; the Airbnb-alumni network is not the Airbnb corporate investment unit. Deal-by-deal participation, pooled LP commitments, platform network totals and personal partner checks are distinct. Exact statutory subscriber vehicles and individual company allocations remain source-specific.

Banking innovation organization combining an alliance, research/advisory institute and investment fund.

BGF is a UK and Ireland investment platform founded in 2011, providing patient minority equity capital to growing private businesses, early-stage science and technology companies, and quoted smaller companies. The retained institutional profile represents the BGF group and its regulated manager BGF Investment Management Limited, FCA reference 771879, wholly owned by BGF Group PLC, company 10657226. Business Growth Fund Limited, company 07514847, is another group entity; the platform’s 2011 founding is distinct from the present PLC’s March 2017 incorporation. Group investment vehicles include BGF Investments LP and separate UK Enterprise Funds developed with Coutts. Its five banking shareholders are Barclays, HSBC, Lloyds, NatWest and Standard Chartered. BGF’s published £3 billion evergreen balance sheet, cumulative £5 billion-plus deployments and sector deployment totals are investment resources and historical activity, not additional external LP fund closes. Published early-stage priorities span life sciences, diagnostics, medical devices, drug discovery, semiconductors, photonics, advanced materials, AI software, energy storage and resource efficiency. Its neuroscience relevance includes TRIMTECH’s research-stage protein-degradation approach, alongside diagnostics and therapeutic technology investment history. Sector investments do not imply product regulatory approval or clinical efficacy. The public team enrichment is explicitly scoped to published leadership, current legal governance and early-stage life-sciences/deep-technology specialists; it does not claim to enumerate all 190-plus group employees. Steven Poulter is retained as a historical Barclays shareholder director because the company register records his resignation on October 6, 2026, although BGF’s website still lists him. Ann McCarthy became company secretary on August 14, 2026. The portfolio and transaction history is preserved; personal investors and unrelated Canadian or Australian growth-fund platforms are not reattributed to BGF.

Ballistic Ventures is an early-stage venture capital manager focused exclusively on cybersecurity and related technology. Its AI relevance includes securing AI systems, detecting synthetic media and disinformation, using AI in data and cloud security, and supporting secure software infrastructure. The manager’s public legal publisher and March27,2026 SEC FormADV identify Ballistic Ventures Alpha LLC, trading as Ballistic Ventures, CRD318512 and exempt-reporting-adviser file802-123294; ERA reporting is distinct from SEC investment-adviser registration. The regulatory principal office is Menlo Park, California. The firm began operating in2021 and publicly launched its inaugural fund in2022. Its current public directory lists fourteen investment, finance, marketing and operating-team members and a separately labelled network of twenty-one external advisers, including named strategic advisers, CISOs-in-Residence and an Entrepreneur-in-Residence. Adviser affiliation does not establish full-time employment or company board membership. Current partner titles supersede historical launch designations; portfolio founders appearing only in testimonials are not manager employees. The five founding partners are Kevin Mandia, Barmak Meftah, Ted Schlein, Jake Seid and Roger Thornton. The firm’s March14,2024 primary announcement confirms the actual USD360M FundII close and retrospectively confirms a closed USD300M inaugural fund; the May17,2022 debut announcement alone described an expected close and does not establish an exact inaugural closing day. Its2026 regulatory filing names five legal fund vehicles, including I and II advisor vehicles and FundA. The April1,2025 FundA SEC filing reported a USD100M offering target and zero sold; no target, gross asset value, aggregate company valuation or portfolio-company ticket is recorded as a cash fund close. The current own portfolio includes Alethea, WitnessAI, GetReal, GombocAI, Noma, MagnitudeAI, AboveSecurity and other cybersecurity companies. Historical businesses funded, founded or operated before Ballistic are separately labelled and are not automatically attributed to this manager; starred partner investments through Area51Ventures remain distinct. Each partner’s existing outside roles, portraits, personal investment graph and private references are preserved. Portfolio cards establish source-qualified backing but not round dates, ticket allocations or lead status. Existing financing identities, including differently named Oligo records and Talon events, remain preserved for separate issuer audits.

British Patient Capital Limited is a wholly owned commercial subsidiary of the British Business Bank and the legal operator of its Patient Capital Funds programme. It supplies long-term capital to innovative UK businesses mainly by committing to venture and venture-growth funds and by co-investing directly alongside supported fund managers in promising later-stage companies. It invests commercially on its own behalf and manages investments for third-party investors. The strategy prioritises venture growth while supporting selected earlier-stage funds to build a later-stage pipeline; relevant themes include life sciences, deep technology and financial services. Its specialist Life Sciences Investment Programme backs later-stage life-sciences fund managers, while Future Fund: Breakthrough provides a separate route for direct investment in R&D-intensive businesses. Fund commitments, programme capacity and direct company financing are distinct. Incorporated in 2018, BPC remains an active legal company (11271076); its public brand and website were brought under the British Business Bank umbrella in 2025.

City Light Capital, publicly branded City Light, is a New York venture capital firm investing in technology businesses whose commercial growth can produce measurable social impact. Its current focus spans care, climate and education, including mental health, addiction treatment, healthcare AI, brain-data software and climate technology. City Spark is its early-stage investment program. Its current published team comprises partners Josh Cohen and Jeff Rinehart, operations leader Grace Cushman, product leader Rohan Nair and engineering leader AD Mohanraj. The exact current legal adviser is City Light Capital Management III, LLC, CRD296787 and SEC exempt reporting adviser file802-113262; this status does not mean SEC registration. Its March26,2026 Form ADV identifies nine legal private funds and co-investment vehicles. Living Cities, an actual limited partner, reports Impact Ventures III as a USD57.4 million fund. Impact Ventures IV reported USD30 million sold in its August31,2020 Form D against a USD100 million target; the sold amount is a filing snapshot, not a verified final close. Portfolio listings establish investment relationships without identifying specific check sizes or financing rounds. Existing historical and personal financial graphs are preserved.

Intermountain Health’s retained investment-platform profile includes its corporate venture program, Intermountain Ventures. The venture arm, established in 2019, invests in healthcare companies and combines capital with clinical validation, operational expertise and commercialization support. Its published focus spans healthcare AI, precision medicine, diagnostics, care-delivery technology, enterprise operations, workforce and consumer experience. Relevant portfolio companies include Octave Bioscience’s multiple-sclerosis biomarkers, Vista.ai’s automated MRI, Sevaro’s neurological care technology, AI therapeutics developer BigHat, Noetik, Freenome and Qualified Health. Legal records distinguish Intermountain Ventures LLC and Intermountain Ventures Fund LLC from the health-system parent. This existing profile preserves historical investor4338 and protected source relationships under their original parent label: some issuer releases name both parent and venture arm, so legacy investments are not attributed wholesale to one LLC. The unit’s own authentic logo and public venture-team information are supplied here with that scope clearly identified. Public biographies verify leadership and several team members; incomplete current titles and shared-service assignments remain qualified. Parent-backed evergreen capital is documented, but a numeric allocation, current AUM and external LP close have not been verified.

KCRise Fund is a venture capital firm that co-invests in early-stage technology businesses with a strategic connection to Kansas or western Missouri, primarily business-to-business companies. It partners with institutional venture and corporate investors in pre-seed, seed and Series A equity rounds of at least $1 million; this is a minimum company round size, not a stated individual investment ticket. Its process combines startup screening, syndication and a final vote by the KCRise Fund board. Founded by Darcy Howe in 2016, the firm connects portfolio companies with regional customers, talent and experienced investors. Published holdings span AI for healthcare administration and vehicle inspection, enterprise software, connected devices, digital health and utility operations. KCRise Capital LLC and KCRise Capital Management LLC operate collectively under the KCRise Fund brand.

LRVHealth is a Boston healthcare venture capital platform founded in 2000, historically operating as Long River Ventures. It invests in early-stage healthcare technology and services with strategic capital from healthcare organizations and works with health systems, payers and entrepreneurs on adoption and commercialization. The current public model describes more than thirty strategic healthcare organizations, rather than independent venture-fund LPs alone. Its AI and neuroscience relevance is grounded in actual portfolio businesses: Cleerly applies AI to cardiovascular imaging, Story Health combines remote cardiology care with AI-supported clinical decisions, Humata Health automates prior authorization, hellocare.ai develops hospital care technology, and Cortica provides autism and neurological care. The firm publishes thirteen staff and fifteen separately identified executive advisors. Own legal disclosures name LRVHealth Ventures, LLC, and its regulatory filing identifies Long River Capital Management II LLC and related LRVHealth fund vehicles. Its fifth historical fund was publicly announced at $200 million raised in May 2023; legal fund numbering differs from historical firm numbering. Regulatory asset values and the healthcare network’s revenue and population statistics are not fund closes or investment checks.

Labcorp is the Burlington, North Carolina laboratory-services corporate group, publicly traded on the NYSE as LH. It provides diagnostic testing, central laboratory and biopharma laboratory services, including molecular diagnostics, precision oncology, proteomics, digital pathology and AI, and neurological disease testing and research. The Labcorp brand was formed in 1995, with older predecessor laboratory operations. A holding-company reorganization completed May 17, 2024 made Delaware Labcorp Holdings Inc. the public successor parent; historical Laboratory Corporation of America Holdings became its wholly owned operating subsidiary. Earlier investments, including Sera Prognostics in 2017 and 2019, refer to that historical operating company, not a newly existing 2024 parent. Labcorp Venture Fund is the group’s strategic corporate investment program, investing since 2012 across diagnostics, biomarkers, precision medicine, digital health, bioinformatics, clinical-trial technology and operational automation. Its current own website reports more than 85 direct investments, more than 50 active investments and over $300 million deployed since 2012; these are cumulative activity figures, not a newly closed external LP fund or AUM. Adam Schechter is chairman, president and CEO. The legacy database InvestmentFirm type and Investor 4310 are retained for reference preservation; this is a corporate group with an internal venture program, not an independent VC partnership. Fortrea clinical development and commercialization services were spun off June 30, 2023.

Oncology Ventures is an early-stage venture capital firm investing in commercially validated companies that improve cancer care and research. Its strategy focuses on healthcare data, software, infrastructure and care delivery rather than developing a broad drug-discovery portfolio. Published themes include earlier detection and precision diagnostics, patient navigation and supportive care, access to clinical data, AI-assisted treatment optimization, oncology workflow automation and digital infrastructure for clinical trials and drug development. The firm works with institutional cancer-care partners and limited partners to evaluate products, support deployment and connect portfolio companies with potential customers. It was founded by Ben Freeberg, whose background combines healthcare investment and operating work at Thyme Care. The legal adviser is Oncology Ventures LLC, an SEC exempt reporting adviser (CRD334395; file802-132161). Its published staff, external advisory board and limited-partner advisory committee have distinct functions.

Reach Capital is an early-stage venture capital firm investing across learning, healthcare and work. Founded in2015 after its partners’ work with NewSchools Venture Fund and the2011 NewSchools Seed fund, it supports pre-seed, seed and SeriesA companies using technology to expand access to education, care and economic opportunity. Current priorities include AI-assisted clinical workflows and healthcare delivery, adaptive education tools, developer technology and workforce systems. Relevant published portfolio examples include Clair Health’s wearable hormone-inference research, Cartwheel and Clayful’s mental-health services, Asha Health’s AI-clinic software, Replit’s AI-assisted development, and GPTZero’s AI-content analysis. Its exact current legal adviser is Reach Management,LLC, an SEC exempt reporting adviser identified by CRD293969 and SEC802-112893, with principal office at474BryantStreet,SanFrancisco. The current public directory distinguishes core staff, an emeritus co-founder and external advisors. Five flagship funds have primary-published sizes of USD53M,82M,165M,215M and265M; the fifth was announced August18,2026. The firm’s reported near-USD1B assets under management also includes separate founders’ and opportunity vehicles and is not treated as an additional fund close. Its typical published check range begins atUSD100K for pre-seed and can exceedUSD12M later; individual portfolio tickets are not inferred from this strategy.

Springbank invests at pre-seed and seed in technology supporting work, household health and wealth, and care delivery. It backs software and services for frontline workers, small businesses, healthcare and caregiving, including companies applying AI and data to these systems. The firm began as Springbank Collective in 2020.

Wavemaker Three-Sixty Health, also branded Wavemaker360, is a Pasadena-based healthcare venture manager focused primarily on seed investments and follow-on SeriesA/B financing. Its thesis spans healthcare AI, computer vision, medical devices, digital health, clinical software, precision healthcare, telehealth, pharma technology and healthcare marketplaces. Its published FAQ excludes drug-discovery biopharma. The firm uses a healthcare-industry LP network to help founders with diligence and commercialization; it has a NewYork office and considers US-focused companies in Canada, Europe and Asia. It is distinct from Singapore-based WavemakerPartners and its broader venture strategies, and from the autonomous Three-Sixty Advisory Group consultancy. The current public operating directory names thirteen people, including JohnNackel founder/generalpartner, JayGoss generalpartner, MaximOwen partner and MattMichelson venturepartner/head ofAI. A separate thirty-seven-person Portfolio Support Alliance is an external LP/adviser support network, not a list of employees or generalpartners. Published2023/2024 strategic councils are historical advisory affiliations. Across these sections, sixty-one distinct people have sixty-six source-qualified roles; stock photo placeholders are excluded and authentic original portraits preserved where available. Official SEC filings establish legal parallel FundII/IIA vehicles and FundIII/GP III with JohnG.Nackel andJayGoss as general-partner managing members. FundII closed atUSD64million, announcedJune9,2022. The existence of FundI and the currentthird fund is verified; their finalclose amounts/exactdates remain unpublished in reviewed primarysources. AUM, portfolio valuations, oldraising targets, and the zero-sold FundIII December2024 filing are not currentclosedfundcash. Source-specific portfolio relevance includes seizure-monitoring Epitel, dementia-support robotics Tombot, AI clinicaltrial analysis, medicalscribes and computationalbiotechnology. Existing institutional andpersonal financialgraphs are preserved; legacy TripleBlind repeatedUSD24M roundrecords are queuedforfullissueraudit rather than silently treated as threenewraises.

Frist Cressey Ventures (FCV) is a healthcare venture capital firm founded in2016 by Bill Frist and Bryan Cressey, with offices in Nashville and New York. The regulated manager identity is Frist Cressey Ventures Management, LLC, SEC exempt reporting adviser CRD299793; this is distinct from separate healthcare private equity firm Cressey & Company. FCV backs early-stage technology and technology-enabled services that improve care delivery, clinical outcomes, access, affordability and healthcare system integration. Its2026 Fund IV strategy explicitly includes AI-native healthcare businesses. Sourced relationships include Qualified Health, Ambience Healthcare, Carta Healthcare, Blackbird Health and Modicus Prime, covering enterprise healthcare AI, clinical workflow automation, mental health care and pharmaceutical AI compliance. The current public manager roster lists20 people, including co-founder/managing partner Bill Frist, co-founder/senior adviser Bryan Cressey, managing partner Navid Farzad, partner Olivia Capra, partner/COO J. Mark Tipps and operating partner Harrison Frist, who joined inApril2026. The FCV Collective is an external healthcare leadership programme; its cohort members are not imported as employees. The issuer announced an actual oversubscribed USD425M Fund IV final close on18February2026. Parallel LP, QP and feeder vehicles are distinguished from the family aggregate; no amount is assigned to each vehicle without a verified allocation. Other current private vehicles are documented by the March2026 manager Form ADV, with unverified final fund-close sizes left empty. Prior institutional and personal investor records are preserved.

Healthworx is a healthcare innovation and investment platform originally launched within CareFirst. Its published ecosystem comprises Ventures, which directly backs healthcare companies; Studio, which builds and launches healthcare businesses; Accelerator, which supports pre-seed and seed-stage companies; and Funds, which partners with institutional healthcare investors. Its investing focus includes healthcare technology, clinical services, behavioral health and data-driven healthcare delivery. The current Ventures directory names six team members; the Studio separately publishes six builders and their operating titles. This profile retains the existing Healthworx investment identity while distinguishing Studio roles from direct venture investing appointments. Published portfolio relationships and acquisition-derived affiliations do not establish individual investment dates or cash allocations; legal fund closing sizes and a complete platform-wide staff directory remain undisclosed.

INKEF Capital is an Amsterdam-based long-term venture investor in healthcare/life sciences and technology. Its current own sustainability disclosure identifies legal INKEF Capital B.V.; official GLEIF identifies active Dutch company50127837, LEI72450026Z98GXUOVRI24 and current Leidsegracht3,1017NAAmsterdam address. Established in2010 with Dutch pension fund ABP backing, the firm supports early-stage companies through technology development, commercialisation and subsequent growth with investment and operational guidance. Its relevant portfolio spans neuromuscular therapeutics (NMD Pharma), neurostimulation (Salvia BioElectronics and ONWARD), AI medical imaging, drug development, enterprise software and silicon-spin quantum computing. ABP’s audited2016 report records its actual commitment increasing by300M to500M inJune2016; government2024 disclosure corroborates500M historical fund commitments. This is committed investment-vehicle capital, not proof paid-in cash or a new2026 LP fund close. Recent550M cumulative deployment references, portfolio fair values and firm AUM are distinct from fundraising. The live current website names eight people with authentic original portraits; old cached versions naming additional staff are not automatically current. Corné Jansen is still listed by INKEF and credited for2026 portfolio work, while Coalition Capital announced him as its General Partner inJune2024; this affiliation is qualified without guessing exclusive employment. Ivan Burkov’s current NMD Pharma General Partner biography and existing Salvia board history/photo are preserved. The firm’s legal corporate identity, fund commitment, institutional portfolio investments and individual professional roles are kept distinct.

Tokyo-based government-backed venture and growth investment manager established in July 2020 as part of Japan Investment Corporation. It invests across Japanese startups from early-stage deep tech and life sciences through growth and later-stage private companies, and supports direct secondary and post-IPO investments through its opportunity strategy. The firm backs commercialization of research in AI, robotics, space, materials, electronics, biotechnology, drug discovery and healthcare, alongside businesses addressing industrial and social challenges. Its hands-on support includes financing, executive recruitment, industry partnerships, overseas market entry, clinical development, domestic and international listings, and M&A.

Tusk Venture Partners is a New York venture-capital manager co-founded by Bradley Tusk and Jordan Nof in 2016, backing early-stage technology businesses in highly regulated markets. Its published sectors include digital health, enterprise software, financial services, consumer technology and transportation. The legal adviser is Tusk Venture Partners Advisor LLC, identified by SEC CRD 301055 as an exempt reporting adviser; this is not SEC registration or endorsement. Its traditional funds pair capital with regulatory and communications support. The founder’s February 12, 2025 announcement cancelled a fourth flagship raise while retaining support, pro-rata decisions and remaining investment activity for existing funds. The current tusk.vc directory publishes eight investment, platform and operations affiliates. A 2022 own announcement establishes a third flagship close of USD 140M commitments; fund vintage and announcement date differ. Closed commitments do not prove all capital called and paid. The newer Tusk Ventures equity-for-services and selective balance-sheet platform is separately represented under existing Investor 5925. Current own Tusk Ventures chronology distinguishes 2016–2024 traditional funds from 2025+ Tusk Ventures V2. Historical names and shared people do not justify merging protected investment graphs. Exact subscribing fund/SPV is not inferred from a brand name.

W Health Ventures is a healthcare company-creation and venture investment platform building businesses in India and the US–India corridor. Its physicians, operators and technologists research gaps in healthcare delivery, validate solutions with patients, recruit founding teams and provide initial capital and operating support from the pre-idea stage. Its companies span mental health, chronic pain, metabolic care, oncology, pediatrics and healthcare AI and engineering. Everbright Health supports US psychiatry practices delivering advanced interventions for treatment-resistant depression, while Wysa is an AI-guided mental-health investment. W Health Ventures Fund II is managed by W Health Ventures Investment Advisors LLP, the investment manager named in its Indian Category II AIF disclosure. The public directory distinguishes its operating team from external advisors.

Workday Ventures is the internal strategic investment arm of Workday, Inc., the US public enterprise-software company. It was launched in a parent announcement dated July14,2015, focused on data science and machine learning; the current directory’s2018 Funded label refers to the later corporate-capital programme rather than initial unit founding. Its immutable existing InvestmentFirm record and Investor4227 are retained as the venture-unit profile, not evidence of an independently incorporated or externally capitalised investment adviser. The current unit publishes five named professionals: Michael Magaro, Barbry McGann, Sarah Ospina, Savannah Greene and Caroline Rafferty. Their capacities span corporate growth, venture investment and portfolio experience; the parent’s general workforce is not duplicated. Workday announced an initial USD250M venture allocation in February2018 and an additional USD250M corporate commitment in February2023, bringing the current programme capacity toUSD500M. These are corporate investment allocations, not inferred external LP closes or cash already paid to every portfolio company. The exact subscribing legal subsidiary, fund or SPV for individual transactions is unpublished unless an issuer identifies it; the published Workday Ventures buyer is qualified at unit level. Its current portfolio emphasises enterprise AI, software automation, infrastructure and responsible AI, with healthcare-related technology including Sully.ai and care-support platforms. Workday Ventures co-led Comulate’s actual USD20M SeriesB announced February11,2025; an individual ticket and any new company board role are not inferred from the investment. Existing venture participation IDs and personal investment graphs are preserved.

Yosemite is the San Francisco oncology-focused venture investment and research-philanthropy platform launched as an independent firm on August1,2023 after spinning out of Emerson Collective Health. Its regulated legal adviser is Yosemite Management, LLC, CRD326764 / SEC801-128248, headquartered at901BatteryStreet, SanFrancisco. The predecessor health strategy began at Emerson in2015; that history is distinct from the standalone2023 launch and manager ownership recorded from2022. Unrelated Japanese Yosemite, Yosemite Capital Management, Yosemite Conservancy and CRED’s Yosemite product are excluded. The firm finances therapeutics, diagnostics, tools, digital health and healthcare delivery, with a cancer non-lethal mission and verified AI drug-discovery/healthcare-software investments. It combines venture investing and incubation with a parallel donor-advised charitable grant programme. Its own February2026 release reports morethanUSD18M cumulatively deployed in research grants since2023; that is not a new debt round, paid LP corpus or a second corporate raise. The2023 launch states that Yosemite manages Emerson Health’s legacy ECI Health Funds as adviser; this does not retroactively change those historical subscribing buyers. Three March2026 SEC-reported private vehicles are separately recorded: Yosemite Fund I LP, Yosemite Fund II LP and Firefall Fund I LP. Primary counsel confirms USD200M first closing for FundI, while the issuer describes an oversubscribed200M+ firstclose; no unproved263M final corpus is inferred from its262.908M grossassetvalue. Own FundII announcement confirms morethan200M initialclose, whose exact corpus remains unpublished;350M is a target. Its January2026 FormD zero sold is a filing-date snapshot before later commencement, and March2026 ADV259.469M GAV is not closed LP commitments. Firefall is an affiliated private vehicle with unpublished corpus. The live firm website does not publish a complete staff or portfolio directory. This profile includes sixteen publicly named operating/legal affiliates and source-qualified historical/advisory roles; private headcount and unverified current ranks are not invented. AnnaDarbyshire’s former foundingCOO role and own transition to adviser are separated. Six genuine named portraits remain unavailable from accessible primary sources. Historical portfolio records and personal checks are preserved, including sparse ChaiDiscovery and duplicate Sage/SageCare representations queued for full issuer audits. Fourier Health’s actual8.4M seed announcedOctober17,2025 explicitly names Yosemite as lead; its individual check and subscribing fund are unpublished.

Amplitude Ventures is a Canadian life-sciences venture investor and biotechnology company builder focused on precision medicine at the intersection of biology and AI. It backs therapeutic platforms, drug-discovery technologies and companies developing treatments matched to disease mechanisms and patient biology. Its published focus includes neurology and neurovascular disease, cancer, immunology and inflammation, metabolic disorders and rare diseases. Through its internal Pre-Amp venture studio, the firm develops scientific hypotheses, incubates technologies and helps assemble new biotechnology companies. It also supports existing companies with financing, business development and scientific strategy.

Aster Capital is a French venture capital firm investing in deep technology, industrial innovation and climate solutions. It finances startups and connects them with corporate customers and industry specialists to help commercialize and scale industrial technologies. Founded in 2000, it also acquires secondary venture portfolios. Its regulated manager, Aster Capital Partners SAS, manages Asternova Centru and Asternova Vest, regional Romanian funds developed with Iceberg+ and Venture Booster for pre-seed through Series A technology companies.

Bpifrance is France’s public investment and business-financing group, supporting companies through credit, state-backed guarantees, innovation grants and repayable advances, direct equity and fund-of-funds investments, export insurance and business support. The retained platform record covers the public Bpifrance brand; it is not a claim that every underlying loan, grant, equity subscription or fund is made by one legal entity. Current own legal notices identify Bpifrance SA, RCS Créteil320252489, with its Maisons-Alfort headquarters, and distinguish the regulated portfolio manager Bpifrance Investissement SAS, RCS433975224, AMF GP-01006. Historic Bpifrance Financement and dedicated investment/insurance subsidiaries or managed vehicles require transaction-specific attribution. Current own media directory publishes13 executive committee leaders, and current Funds of Funds pages publish37 additional scoped management, investment, operating, retail and digital professionals; these are published scope, not the group’s complete employee headcount. The older2017 press contacts page is not treated as the current roster. Capital Innovation supports biotechnology, medical devices, digital health, AI and deeptech. InnoBio3 reached its definitive EUR207M size in September2026 and explicitly invests in neurosciences; InnoBioI/II actual reported corpora173M/203M are separate funds. Other health funds include Patient Autonome and Prévention Numérique en santé. Group statutory share capital, assets under management, lending guarantees, innovation allocations and government programme budgets are not recorded as closed LP funds. Portfolio-card dates or accelerator membership alone do not establish a priced cash round. Acticor’s own2021 registration identifies actual2020 Bpifrance loan financing separately from the bank’s guarantee administration and the separate CIC Ouest loan; its issuer owner controls the qualified financial link. Own January8,2021 legal reorganisation announcement proves that on December18,2020 Bpifrance Financement absorbed the former Bpifrance SA holding and itself adopted the name Bpifrance, with unchangedRCS320252489 and headquarters. Thus the November2020 Acticor creditor is the historical same continuing credit institution, rather than a cash buyer inferred from guarantee administration. Bpifrance Investissement remains a distinct regulated management subsidiary.

Early-stage venture capital firm backing European technology companies that help people learn, work and adapt. Its strategy spans educational technology, AI tools for learning and productivity, labor marketplaces and software that helps organizations manage talent and changing workforce needs. The firm invests from pre-seed through Series A and supports founders through investment teams, research, operating support and a mentor network in London and Paris.

Coalition Operators is an early-stage venture capital firm founded by Ashley Mayer, Toyin Ajayi, Lindsay Ullman and Jaclyn Rice Nelson. It invests primarily at pre-seed and seed in artificial intelligence, healthcare, enterprise software, consumer businesses, commerce and other categories where its founders have operating experience. Ashley Mayer is the full-time general partner; the other three co-founders are part-time general partners who bring healthcare, product and enterprise AI experience. The firm also coordinates an external operator network that connects startups with experienced advisers, angels, contractors and customers; network membership does not imply employment, general partner status or a personal financial check. Its published portfolio includes Knit Health, TensorZero, Hamming AI, Journey Clinical and other companies. Coalition Operators, LLC is the exact legal adviser, CRD319229 and SEC exempt reporting adviser file802-135571. Its February2026 Form ADV identifies Fund I, a series of Coalition Operators, LP, reported in detail by Platform Advisor LLC, and Coalition Operators Fund II, LP. Founder Ashley Mayer announced a USD12.5 million LP-backed early-stage fund in2022; its July2022 FormD/A later reported exact actual sold capital of USD12,678,000 for the same Fund I. This later disclosure is not a second cash close. Fund II’s2025 initial offering filing disclosed no sales yet; the current fund’s regulatory asset value is not a verified cash close. All historical institutional and personal participation graphs are preserved.

Idinvest Partners is the historical Paris-based European investment manager founded in 1997, formerly AGF Private Equity. Its activities included venture and growth capital, private debt, industrial asset finance, and primary, secondary and co-investment portfolios. Its venture practice invested in digital technology, smart-city infrastructure and healthcare, including clinical artificial intelligence at Corti, healthcare AI at Sophia Genetics and digital therapeutics. Portfolio exposure is distinguished from an assertion of clinical efficacy or regulatory approval. The archived legal notice identifies Idinvest Partners SA, Paris RCS/SIREN 414735175, AMF approval GP 97-123 and AIFM authorization. Eurazeo completed its original 70% acquisition on April 12,2018, following the February 5 agreement; subsequent 2020 announcements and group reports describe acquisition of the remaining ordinary shares. Acquisition price and the manager’s assets under management are not company funding or LP fund closes. The SEC adviser filing CRD 310884 explicitly records the legal-name change to Eurazeo Investment Manager–EIM. Eurazeo’s own 2025 annual report confirms EIM was absorbed into Eurazeo Global Investor on December 31,2023. Current EGI has a different SIREN 414908624 and AMF approvalGP 97-117. The retained Idinvest historical investor 4113 is distinct from the existing Eurazeo group investor 2609; their prior checks, personal records and source histories are preserved rather than merged. The full August 2020 primary directory contains 132 named historical operating, investment, support and external advisory affiliations. Historical titles are marked expressly and publication date is not treated as employment start or exit day. Strategic advisers and venture partners are distinguished from operating staff; people who later joined other managers retain their other roles and genuine existing portraits. The directory includes founders Christophe Bavière and Benoist Grossmann; managing partners Matthieu Baret, Nicolas Chaudron, François Lacoste, Christophe Simon, Eric Gallerne and Sylviane Guyonnet; and the broader published private-debt, venture, growth, fund-of-funds, finance, operations, legal and investor-relations teams. This is not a claim that an independent Idinvest operating team still exists in 2026. Primary manager and parent reports establish genuine historical fund closes, including DigitalFundII, DigitalFundIII, GrowthFundII, PrivateDebtIV, ISIA and SecondaryFundIV. Program totals, initial targets, first closes and separate retail mandates are distinguished from final fund sizes. The original named retail legal vehicles are included only with source-qualified unknown cash size/closing dates where undisclosed. Historical publisher portraits and the original Idinvest logo are retained; inaccessible archival photographs remain documented gaps. Corti’s issuer researcher owns the sole matching 2021 Idinvest participation, while its 2023 source names Eurazeo separately.

Lifeline Ventures is a Finland-based venture capital firm founded by entrepreneurs that invests at pre-seed and seed and supports companies as they grow. Its sector-agnostic strategy includes software, health and TechBio, hardware, climate technology, energy and defence technology. The team helps founders with hiring, financing, business decisions and international expansion, drawing on operating experience and global networks. Its funds make equity, equity-related and debt investments in software and advanced-technology businesses. The platform operates through two Finnish-regulated managers: registered Lifeline Ventures Fund Management Oy and authorized LLV Fund Management Oy; Fund VI uses a Luxembourg SCSp vehicle. Lifeline is distinct from LifeLine Family Heritage Fund.

S2G Investments is a multi-asset investment firm focused on food and agriculture, energy and oceans. Founded in 2014, it invests across late-stage venture, growth equity, structured finance and infrastructure to help companies commercialize technologies for the physical economy. Its AI and deep technology investments include warehouse robotics, agricultural automation, industrial electrification, maritime batteries and sensing systems. Examples in its public directory include Corvus Robotics, Aerones, Formic and Unseenlabs. The firm changed its name from S2G Ventures to S2G Investments in February 2025. It reported $2.8 billion in assets under management and more than 120 investments at the final closing of its $1 billion Solutions Fund I in May 2026. Its current public team directory lists 65 people, led by Managing Partners Aaron Rudberg, Chuck Templeton and Sanjeev Krishnan, and includes investment, operations, legal, ecosystem and AI specialists. S2G co-led Corvus Robotics' seed and Series A funding program described in October 2024 and participated in its $20 million Series A-2 announced August 2026.